CSIMarket Company Name, Ticker, Customers, else..
 
Neurometrix Inc   (NASDAQ: NURO)
Other Ticker:  
 
 
Price: $4.0500 $0.12 3.053%
Day's High: $4.05 Week Perf: 1 %
Day's Low: $ 3.98 30 Day Perf: 3.85 %
Volume (M): 2 52 Wk High: $ 4.73
Volume (M$): $ 6 52 Wk Avg: $3.82
Open: $4.05 52 Wk Low: $2.66



 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 2
 Employees 60
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Neurometrix Inc
NeuroMetrix Inc is a medical device company that focuses on developing and commercializing advanced technologies to aid in the diagnosis and treatment of chronic diseases, particularly those involving the nervous system. The company's flagship product is the Quell device, a wearable neurostimulation device that provides non-invasive pain relief for individuals suffering from chronic pain conditions such as neuropathy, fibromyalgia, and arthritis. In addition to pain management, Neurometrix is also engaged in the development of other medical technologies, including testing platforms and molecular biomarkers, aimed at improving patient care and outcomes. The company is headquartered in Waltham, Massachusetts and operates globally.


   Company Address: 4B Gill Street Woburn 1801 MA
   Company Phone Number: 890-9989   Stock Exchange / Ticker: NASDAQ NURO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AXNX        0.8% 
BSX        4.28% 
INSP        1.28% 
MDT        7.69% 
NVRO        13.4% 
SYK        6.22% 
• View Complete Report
   



Merger and Acquisition

NeuroMetrix Set to Join Forces with electroCore: A Strategic Move to Revolutionize Chronic Disease Management

Published Tue, Dec 17 2024 9:05 PM UTC

Breaking News: NeuroMetrix Enters Definitive Merger Agreement with electroCore, Inc.August 13, 2024 ? In a significant development in the medical technology sector, NeuroMetrix Inc. (NASDAQ: NURO), a pioneer in wearable therapeutic devices and diagnostic products, has announced a definitive merger agreement with electroCore, Inc. This strategic move is poised to enhance the ...
Management Announcement

NeuroMetrix Explores New Horizons: A Deep Dive into the Company's Strategic Alternatives

Published Tue, Aug 13 2024 6:48 PM UTC



In August 2024, NeuroMetrix, Inc., a leading player in the field of medical technology, made a significant announcement that it has initiated a comprehensive review of strategic alternatives. This move took the financial world by storm, with industry experts and investors eagerly speculating on the potential outcomes and the company s future trajectory. NeuroMetrix...
Neurometrix Inc

NeuroMetrix Inc Faces Rising Losses and Dwindling Revenues in Q1 2024

NeuroMetrix Inc Reports Increased Losses and Declining Revenues for Q1 2024
In the fiscal interval of January to March 31, 2024, NeuroMetrix Inc, a pioneering healthcare firm specializing in wearable medical technology, experienced a loss per share of $-1.67. This represents an increase from the loss of $-1.60 per share in the previous year and a larger loss compared to the preceding financial reporting period where the loss per share was $-1.27. The company's financial performance has been impacted by these losses.
Additionally, NeuroMetrix Inc's revenue for the same financial reporting period decreased by -36.597% to $1.09 million from $1.72 million in the previous year. However, there was a sequential doubling of revenue by 200.647% from $0.36 million. This decline in revenue reflects the challenges faced by the company in generating profits.
Contract

NeuroMetrix Prioritizes Increased Shareholder Value Following Strategic Steps and Valuable Shareholder Feedback.

Published Fri, Apr 19 2024 12:00 PM UTC

NeuroMetrix, a pioneering health-care firm focusing on developing and marketing cutting-edge wearable medical technology, today announced significant strides taken to increase shareholder value. This recent came into action following valuable feedback and advice from one of its most significant shareholders. The aim was to create and establish better and stronger financial ...
Clinical Study

Novel Study Confirms the Accuracy of DPNCheck in Diagnosing Diabetic Peripheral Neuropathy

Published Thu, Mar 14 2024 1:00 PM UTC

presents remarkable findings from a recent publication by NeuroMetrix, Inc., announcing the successful detection of diabetic peripheral neuropathy (DPN) using DPNCheck technology. The study highlights the effectiveness of DPNCheck as a standalone method or in combination with standard electrocardiography (EKG) for accurately diagnosing DPN.Study Overview:In a groundbreaking...






Neurometrix Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com